---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-23-000134"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T08:18:34.180279+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Senti Bio receives FDA IND clearance for SENTI-202 CAR-NK therapy for AML

## Summary
- FDA cleared IND for SENTI-202, an off-the-shelf CAR-NK cell therapy targeting CD33/FLT3 hematologic malignancies including AML.
- Phase 1 trial expected to treat first patient in Q2 2024 at multiple US and Australia sites.
- Initial efficacy data expected by year-end 2024; durability data expected in 2025.
- Trial evaluates two dose levels (1 or 1.5 billion cells) with three weekly doses after lymphodepletion and optional continuation cycles.
- Manufacturing expenses for Phase 1 largely prepaid through existing GeneFab agreement.

## SEC filing metadata
- accession: 0001854270-23-000134
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000134/0001854270-23-000134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000134/snti-20231222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-23-000134
- JSON: https://secwatch.observer/filing/0001854270-23-000134.json
- Plain text: https://secwatch.observer/filing/0001854270-23-000134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.